RasGAP-derived peptide 38GAP potentiates the cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-κB in colon carcinoma HCT116 cells

Cancer Letters

Volumn 308, Issue 1, 2011, Pages 62-70

  Zhang, Hao ^a   Zhang, Shenghua ^a   He, Hongwei ^a   Zhao, Wuli ^a   Ren, Kaihuan ^a   Chen, Jianhua ^b   Shao, Rong guang ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Wuhan KatyGen Pharmaceuticals Inc   (China)

Author keywords

38GAP; Apoptosis; CDDP; Chemosensitization; Colon cancer

Indexed keywords

38GAP PEPTIDE; CISPLATIN; CYCLIN DEPENDENT KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; COLON CANCER; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MONOTHERAPY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SEQUENCE ANALYSIS; TREATMENT DURATION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CISPLATIN; COLONIC NEOPLASMS; DNA DAMAGE; DOWN-REGULATION; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GTPASE-ACTIVATING PROTEINS; HCT116 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-AKT;

ANIMALIA;

EID: 79958089345     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.014     Document Type: Article

References (46)

1. Wolpin B.M., Mayer R.J. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310.
2. Siddik Z.H. Cisplatin mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
3. Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 2005, 9:59-71.
4. Fransen K., Klintenas M., Osterstrom A., Dimberg J., Monstein H.J., Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25:527-533.
5. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., Futreal P.A., Stratton M.R., Wooster R., Leung S.Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002, 62:6451-6455.
6. Fang J.Y., Richardson B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005, 6:322-327.
7. Repasky G.A., Chenette E.J., Der C.J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell. Biol. 2004, 14:639-647.
8. Parsons D.W., Wang T.L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., Velculescu V.E. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436:792.
9. Velho S., Oliveira C., Ferreira A., Ferreira A.C., Suriano G., Schwartz S., Duval A., Carneiro F., Machado J.C., Hamelin R., Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer 2005, 41:1649-1654.
10. Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005, 10:2986-3001.
11. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
12. Balmanno K., Chell S.D., Gillings A.S., Hayat S., Cook S.J. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int. J. Cancer 2009, 125:2332-2341.
13. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
14. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
15. Michod D., Yang J.Y., Chen J., Bonny C., Widmann C. A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. Oncogene 2004, 23:8971-8978.
16. Yang J.Y., Widmann C. Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP. Mol. Cell. Biol. 2001, 21:5346-5358.
17. Yang J.Y., Widmann C. The RasGAP N-terminal fragment generated by caspase cleavage protects cells in a Ras/PI3K/Akt-dependent manner that does not rely on NFkappa B activation. J. Biol. Chem. 2002, 277:14641-14646.
18. Yang J.Y., Walicki J., Michod D., Dubuis G., Widmann C. Impaired Akt activity down-modulation, caspase-3 activation, and apoptosis in cells expressing a caspase-resistant mutant of RasGAP at position 157. Mol. Biol. Cell. 2005, 16:3511-3520.
19. Michod D., Annibaldi A., Schaefer S., Dapples C., Rochat B., Widmann C. Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice. J. Natl. Cancer Inst. 2009, 101:828-832.
20. Pittet O., Petermann D., Michod D., Krueger T., Cheng C., Ris H.B., Widmann C. Effect of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light. J. Photochem. Photobiol. B 2007, 88:29-35.
21. Rehm M., Huber H.J., Dussmann H., Prehn J.H. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J. 2006, 25:4338-4349.
22. Michod D., Widmann C. TAT-RasGAP317-326 requires p53 and PUMA to sensitize tumor cells to genotoxins. Mol. Cancer Res. 2007, 5:497-507.
23. W. Cui, Z. Wei, Q. Chen, Y. Cheng, L. Geng, J. Zhang, J. Chen, T. Hou, M. Ji, Structure-based design of peptides against G3BP with cytotoxicity on tumor cells, J. Chem. Inform. Model 50 380-387.
24. Sun H.X., He H.W., Zhang S.H., Liu T.G., Ren K.H., He Q.Y., Shao R.G. Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition. Cancer Gene Ther. 2009, 16:693-702.
25. Ren K., Jin H., Bian C., He H., Liu X., Zhang S., Wang Y., Shao R.G. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J. Biol. Chem. 2008, 283:35598-35605.
26. Ando T., Kawabe T., Ohara H., Ducommun B., Itoh M., Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J. Biol. Chem. 2001, 276:42971-42977.
27. Kulkarni S.V., Gish G., van der Geer P., Henkemeyer M., Pawson T. Role of p120 Ras-GAP in directed cell movement. J. Cell. Biol. 2000, 149:457-470.
28. Tocque B., Delumeau I., Parker F., Maurier F., Multon M.C., Schweighoffer F. Ras-GTPase activating protein (GAP): a putative effector for Ras. Cell Signal. 1997, 9:153-158.
29. Dent P., Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin. Cancer Res. 2001, 7:775-783.
30. Yue Y., Lypowy J., Hedhli N., Abdellatif M. Ras GTPase-activating protein binds to Akt and is required for its activation. J. Biol. Chem. 2004, 279:12883-12889.
31. Dolcet X., Llobet D., Pallares J., Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005, 446:475-482.
32. Y. Dai, S. Grant, New insights into checkpoint kinase 1 in the DNA damage response signaling network, Clin. Cancer Res. 16 376-383.
33. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277:1501-1505.
34. Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H., Elledge S.J. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997, 277:1497-1501.
35. Wang R., He G., Nelman-Gonzalez M., Ashorn C.L., Gallick G.E., Stukenberg P.T., Kirschner M.W., Kuang J. Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell 2007, 128:1119-1132.
36. Trahey M., McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987, 238:542-545.
37. Wen L.P., Madani K., Martin G.A., Rosen G.D. Proteolytic cleavage of ras GTPase-activating protein during apoptosis. Cell Death Differ. 1998, 5:729-734.
38. Widmann C., Gibson S., Johnson G.L. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J. Biol. Chem. 1998, 273:7141-7147.
39. Yang J.Y., Michod D., Walicki J., Murphy B.M., Kasibhatla S., Martin S.J., Widmann C. Partial cleavage of RasGAP by caspases is required for cell survival in mild stress conditions. Mol. Cell. Biol. 2004, 24:10425-10436.
40. Wang X., Martindale J.L., Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 2000, 275:39435-39443.
41. Yeh P.Y., Chuang S.E., Yeh K.H., Song Y.C., Ea C.K., Cheng A.L. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem. Pharmacol. 2002, 63:1423-1430.
42. Barnes C.J., Li F., Mandal M., Yang Z., Sahin A.A., Kumar R. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res. 2002, 62:1251-1255.
43. French J., Stirling R., Walsh M., Kennedy H.D. The expression of Ras-GTPase activating protein SH3 domain-binding proteins, G3BPs, in human breast cancers. Histochem. J. 2002, 34:223-231.
44. Guitard E., Parker F., Millon R., Abecassis J., Tocque B. G3BP is overexpressed in human tumors and promotes S phase entry. Cancer Lett. 2001, 162:213-221.
45. Liu Y., Zheng J., Fang W., You J., Wang J., Cui X., Wu B. Identification of metastasis associated gene G3BP by differential display in human cancer cell sublines with different metastatic potentials G3BP as highly expressed in non-metastatic. Chin. Med. J. (Engl.) 2001, 114:35-38.
46. Chen W., Wang X., Bai L., Liang X., Zhuang J., Lin Y. Blockage of NF-kappaB by IKKbeta- or RelA-siRNA rather than the NF-kappaB super-suppressor IkappaBalpha mutant potentiates adriamycin-induced cytotoxicity in lung cancer cells. J. Cell. Biochem. 2008, 105:554-561.